Retrospective analysis of the efficacy, safety, and technical parameters of middle meningeal artery embolization using MagicGlue

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038414

Enrollment

180

Registered

2025-12-23

Start date

2026-01-02

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic subdural hemaotoma

Interventions

Group 1: Patients who underwent middle meningeal artery embolization using N-hexyl-cyanoacrylate (NHCA) Group 2: Patients who a) did not undergo MMA embolization but received burr-hole trepanation or

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: MMA embolization performed with Magic Glue or Squid, or burr-hole trepanation for cSDH performed before the introduction of MMA embolization at the University Hospital Bonn (UKB).

Exclusion criteria

Exclusion criteria: a) missing 90-day follow-up; b) missing or inadequate imaging documentation

Design outcomes

Primary

Measure	Time frame
Rate of patients requiring repeat surgery for subdural hematoma within 180 days. Data are collected from the institution’s PACS, RIS, and electronic patient records.	—

Secondary

Measure	Time frame
Contrast-to-noise ratio in fluoroscopic imaging Visibility as assessed by neurointerventionalists using a Likert scale	—

Countries

Germany

Contacts

Public ContactNils Christian Lehnen

Universitätsklinikum Bonn

nils.lehnen@ukbonn.de022828731405

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026